Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

• Published in: Cancer medicine (Malden, MA) Vol. 10; no. 2; pp. 563 - 574
• Main Authors: Yan, Lingzhi, Qu, Su, Shang, Jingjing, Shi, Xiaolan, Kang, Liqing, Xu, Nan, Zhu, Mingqing, Zhou, Jin, Jin, Song, Yao, Weiqin, Yao, Ying, Chen, Guanghua, Chang, Huirong, Zhu, Xiaming, Yu, Lei, Wu, Depei, Fu, Chengcheng
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2021; John Wiley and Sons Inc; Wiley
• Subjects: Antigens; Biomarkers; CD19 antigen; Chemotherapy; chimeric antigen receptor T (CAR T) cell; Chimeric antigen receptors; Clinical Cancer Research; Clinical trials; Cytokines; dose‐escalation; Drug dosages; efficacy; Lymphocytes; Lymphocytes T; Multiple myeloma; Original Research; Patients; Plasma; relapsed and/or refractory; Remission; Remission (Medicine); safety; Toxicity; multiple myeloma; relapsed and/or refractory; chimeric antigen receptor T (CAR T) cell; dose-escalation; safety; efficacy

The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell...